Update on immunopathogenesis and immunotherapy in multiple sclerosis

被引：24

作者：

Selter, Rebecca C. ^{[1
]}

Hemmer, Bernhard ^{[1
,2
,3
]}

机构：

[1] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, Ismaninger Str 22, D-81675 Munich, Germany

[2] Munich Cluster Syst Neurol, Munich, Germany

[3] Competence Network Multiple Sklerosis, Munich, Germany

来源：

IMMUNOTARGETS AND THERAPY | 2013年 / 2卷

关键词：

multiple sclerosis; immunopathogenesis; disease-modifying therapy;

D O I：

10.2147/ITT.S31813

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system. Both genetic and environmental factors are believed to contribute to the pathogenesis of the disease. Histopathological findings suggest that multiple sclerosis is an immune-mediated disease, involving both the cellular and humoral immune systems. Within the last 20 years, several disease-modifying therapies for the treatment of multiple sclerosis were established. Moreover, promising new substances are currently being tested in clinical trials and will likely broaden the therapeutic opportunities available within the upcoming years.

引用

页码：21 / 30

页数：10

共 91 条

[1] Immunopathology or organ-specific autoimmunity as a consequence of virus infection [J].

Aichele, P ;

Bachmann, MF ;

Hengartner, H ;

Zinkernagel, RM .

IMMUNOLOGICAL REVIEWS, 1996, 152 :21-45

[2] Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors [J].

Ascherio, Alberto ;

Munger, Kassandra L. .

ANNALS OF NEUROLOGY, 2007, 61 (06) :504-513

[3] Environmental risk factors for multiple sclerosis. Part I: The role of infection [J].

Ascherio, Alberto ;

Munger, Kassandra L. .

ANNALS OF NEUROLOGY, 2007, 61 (04) :288-299

[4] Vitamin D and multiple sclerosis [J].

Ascherio, Alberto ;

Munger, Kassandra L. ;

Simon, K. Claire .

LANCET NEUROLOGY, 2010, 9 (06) :599-612

[5] Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion [J].

Barnett, MH ;

Prineas, JW .

ANNALS OF NEUROLOGY, 2004, 55 (04) :458-468

[6] The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of copolymer 1 on MOG-induced disease [J].

BenNun, A ;

Mendel, I ;

Bakimer, R ;

FridkisHareli, M ;

Teitelbaum, D ;

Arnon, R ;

Sela, M ;

deRosbo, NK .

JOURNAL OF NEUROLOGY, 1996, 243 (04) :S14-S22

[7] Monoclonal antibodies in MS Mechanisms of action [J].

Bielekova, Bibiana ;

Becker, Brenda L. .

NEUROLOGY, 2010, 74 (01) :S31-S40

[8] Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy [J].

Bloomgren, Gary ;

Richman, Sandra ;

Hotermans, Christophe ;

Subramanyam, Meena ;

Goelz, Susan ;

Natarajan, Amy ;

Lee, Sophia ;

Plavina, Tatiana ;

Scanlon, James V. ;

Sandrock, Alfred ;

Bozic, Carmen .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (20) :1870-1880

[9] Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis [J].

Brinkmann, Volker ;

Billich, Andreas ;

Baumruker, Thomas ;

Heining, Peter ;

Schmouder, Robert ;

Francis, Gordon ;

Aradhye, Shreeram ;

Burtin, Pascale .

NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (11) :883-897

[10]

Bruck W, 2003, J NEUROL SCI, V206, P181, DOI 10.1016/S0022-510X(02)00191-0

← 1 2 3 4 5 6 7 8 9 10 →